Article Figures & Data
Figures
- Fig. 1.
Diagnostic value of serum osteopontin and mesothelin in patients with MPM. A, serum osteopontin values in MPM patients compared with pleural metastasis (Mets), benign pleural lesions associated with asbestos exposure (BPLAE), and healthy asbestos-exposed subjects (AE). B, serum mesothelin in same patients. Horizontal lines, median values (A and B). C, ROC curve for mesothelin and osteopontin when differentiating between MPM and healthy asbestos-exposed subjects (AE group).
- Fig. 2.
ROC curve for serum mesothelin and osteopontin to distinguish patients with any pleural involvement (MPM, BPLAE, or Mets) and healthy asbestos-exposed patients (AE; A) and patients with malignant (MPM and Mets) and benign pleural involvement (BPLAE and AE; B).
- Fig. 3.
Pleural values of osteopontin (A) and mesothelin (B) in patients with MPM, pleural metastasis of carcinoma (Mets), and benign pleural lesions associated with asbestos exposure (BPLAE). Horizontal lines, median values.
- Fig. 4.
Kaplan-Meier survival curves in the subgroup of patients with MPM. A, difference between different mesothelioma histologic subtypes. B, survival in patients with high (>3.5 nmol/L) or low (<3.5 nmol/L) serum mesothelin C, survival curves according to high (>350 ng/mL) and low (<350 ng/mL) serum osteopontin. Number under each graph represents mean numbers of individuals at risk for each period.
Tables
- Table 1.
Demographic data of recruited patients
Mets (n = 43) BPLAE (n = 33) MPM (n = 96) AE (n = 112) Age, y (mean ± SD) 66.1 ± 11.2 62.2 ± 10.5 65 ± 9.7 63 ± 6.8 Male gender, n (%) 24 (56) 32 (97) 78 (81) 95 (84) Mode of diagnosis, n (%) Blind pleural biopsy 2 (4.7) — 1 (1) NA Thoracoscopy 29 (67.4) 22 (66.7) 60 (62.5) Surgery (VATS or open surgery) 8 (18.6) 11 (33.3) 31 (32.3) Guided biopsy (CT or US) 4 (9.3) — 4 (4.1) Confirmed asbestos exposure, n (%) 15 (34.9) 28 (84.8) 82 (85.4) 112 (100) Survival, median (95% CI) mos* 9 (6-12) — 14 (10-18) NA Staging (IMIG classification)† Stage I NA NA 11 NA Stage II 21 Stage III 32 Stage IV 19 Abbreviations: VATS, video-assisted thoracoscopic surgery; CT, chest computed tomography scan; US, ultrasound; IMIG, International Mesothelioma Interest Group; NA, not applicable.
↵* Median survival was not calculated for the BPLAE group; only three (9.1%) deaths were noted in this group, one due to one bronchial adenocarcinoma and two nonneoplastic, non-asbestos–related deaths.
↵† Complete tumor-node-metastasis staging was available for 83 patients.
- Table 2.
AUCs for different comparisons
Any pleural disease vs AE* AUC (95% CI) Malignant vs benign pleural disease† AUC (95% CI) Serum osteopontin 0.735 (0.677-0.793) 0.710 (0.647-0.773) Plasma osteopontin — 0.729 (0.631-0.827)‡ Pleural osteopontin — 0.478 (0.332-0.624)‡ Serum mesothelin 0.741 (0.684-0.799) 0.784 (0.727-0.842) Pleural mesothelin — 0.646 (0.542-0.749)‡ - Table 3.
Survival analysis in MPM patients
Variables Categories Univariate analysis Multivariate analysis HR (95% CI) P HR (95% CI) P Tumor stage* 0.058 — — Histologic subtype Epithelioid — — — — Biphasic 0.91 (0.37-2.24) 0.848 0.943 (0.350-2.539) 0.908 Sarcomatoid 4.08 (1.72-9.66) 0.001 6.683 (2.525- 17.683) 0.001 Serum mesothelin >3.5 nmol/L 2.39 (1.247-4.583) 0.009 2.785 (1.384-5.607) 0.004 Pleural mesothelin Continuous 0.994 (0.988-1.001) 0.118 ND — Serum osteopontin >350 ng/mL 5.263 (1.875-14.777) 0.002 3.459 (1.098-10.895) 0.034 Plasma osteopontin Continuous 1.001 (1.000-1.001) 0.001 ND — Pleural osteopontin Continuous 1.000 0.259 ND — Abbreviation: ND, not done.
↵* Tumor stage was not retained as an independent prognostic factor in the multivariate analysis.
Volume 13, Issue 10
